News & Publications

Representation of Luminera Derm in the Sale of its Dermal Business to AbbVie

Representation of Luminera Derm Ltd. and its affiliated companies in a share and asset transaction, pursuant to which Luminera sold its dermal filler portfolio and R&D pipeline to AbbVie Inc. (NYSE: ABBV) unit Allergan Aesthetics, for a consideration of hundreds of millions of dollars. Luminera Derm is an R&D company as well as a manufacturer […]

Raz Tepper & Sharon Klein-Manbar & Ziv Schwartz & Sharona Haim Pour - Abramovich & Yuval Peled & Ben Strauss & Hila Zackay & Audrey Abensur & Moran Friedman | Oct 2020 | Transaction

Representation of Frutarom Industries Ltd. in its Acquisition of Enzymotec Ltd.

FBC represented Frutarom Industries Ltd. in its acquisition of Enzymotec Ltd. (NASD: ENZY), for approximately $210 million, at an equity value of approximately $290 million. Enzymotec is a leading global supplier of specialty lipid-based products and solutions. Prior to the merger, Frutarom had acquired approximately 19% of Enzymotec’s shares and announced its intention to make […]

Avraham Well & Sharon Rosen & Zohar Liss & Ziv Schwartz & Moran Friedman & Hilla Sachs | Jan 2018 | Transaction

FBC represented SKY and Kedman Capital in the purchase of 70% of S.AL Holdings Ltd.

FBC represented the SKY and Kedma Capital private equity funds in a transaction for the purchase of 70% of the shares of S.AL Holdings Ltd., in consideration of approximately NIS 136.5M. The consummation of the transaction is subject to the approval of the Israel Antitrust Authority. S.AL Holdings, a leading company in the field of […]

Raz Tepper & Sharon Klein-Manbar & Michael Zellermayer & Ziv Schwartz | Jul 2017 | Transaction

FBC advises Qualcomm in its acquisition of CSR’s imaging unit for approximately $45M

FBC advises Qualcomm in its acquisition of CSR’s imaging unit for approximately $45M

Raz Tepper & Ronald Lehmann & Amit Dat & Moran Friedman & Ziv Schwartz | Jul 2014 | Transaction